CDXC - ChromaDex Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.38
-0.04 (-0.90%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.42
Open4.40
Bid4.38 x 100
Ask4.72 x 1500
Day's Range4.35 - 4.51
52 Week Range2.86 - 7.24
Volume128,801
Avg. Volume355,069
Market Cap240.315M
Beta0.78
PE Ratio (TTM)N/A
EPS (TTM)-0.37
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.25
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Fourth Published Clinical Trial Confirms Long-Term Safety of NIAGEN® Supplementation at High Doses and Shows Potential for Improvement in Liver Health

    ChromaDex Corp. (CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from a human clinical study of NIAGEN®, a novel form of vitamin B3, at University of Copenhagen and Aarhus University Hospital, were published yesterday in The American Journal of Clinical Nutrition. The authors conducted a 12-week, randomized, double-blinded, placebo-controlled, parallel-group clinical trial in 40 middle-aged obese men taking a 2 gram dose (1 gram twice daily) of NIAGEN nicotinamide riboside chloride (NR).

  • GlobeNewswire13 days ago

    TRU NIAGEN® to be featured at the American Association of Naturopathic Physicians Annual Convention and the 2018 Healthy Aging Summit

    ChromaDex Corp. (CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it will feature its flagship consumer product to help improve the aging process, TRU NIAGEN®, at the American Association of Naturopathic Physicians Annual Convention as well as the 2018 Healthy Aging Summit. The sole active ingredient in TRU NIAGEN is nicotinamide riboside, a unique form of vitamin B3 clinically proven to safely increase one’s levels of NAD (nicotinamide adenine dinucleotide). The American Association of Naturopathic Physicians Annual Convention will take place in San Diego, CA, from July 12-14—TRU NIAGEN will exhibit at booth #606.

  • GlobeNewswire27 days ago

    ChromaDex added to membership of US small-cap Russell 2000® Index

    ChromaDex Corp. (CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today it was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on June 25, as part of the 2018 Russell indexes reconstitution. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell indexes are part of FTSE Russell, a leading global index provider.

  • GlobeNewswirelast month

    Research Report Identifies ChromaDex, W.P. Carey, Rambus, Dynex Capital, Home BancShares, and Granite Construction with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, June 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ChromaDex ...

  • CNW Grouplast month

    Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update

    VANCOUVER , June 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Board of Directors (the "Board") has elected Steve Rubin as Chairman of the Board, effective immediately. "I am honored to have the opportunity to work more closely with Fred and the rest of the Neovasc team as we advance the Company's development and commercial strategy for the Tiara and Reducer," stated Mr. Rubin.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CDXC earnings conference call or presentation 10-May-18 8:30pm GMT

    Q1 2018 Chromadex Corp Earnings Call

  • GlobeNewswire2 months ago

    ChromaDex Appoints Lisa Bratkovich as Chief Marketing Officer

    ChromaDex Corp. (CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it has appointed Lisa Bratkovich as Chief Marketing Officer, effective today. Bratkovich is joining ChromaDex from Direct Upside Group, a direct-to-consumer marketing and customer experience transformation consulting firm, where she has served as CEO and Principal since 2016. Prior to starting her own firm, Bratkovich spent 13 years at Guthy|Renker, where she served as Senior Vice President of Marketing.

  • GlobeNewswire2 months ago

    TRU NIAGEN® to be featured at the American Society for Nutrition's Annual Meeting

    ChromaDex Corp. (CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it will feature its novel form of vitamin B3, TRU NIAGEN® (Booth #405), at the American Society for Nutrition's Annual Meeting, a gathering of 2500 scientists, healthcare practitioners, researchers and policy makers, June 9-12 in Boston, MA. Members of the TRU NIAGEN team will be on site to discuss the scientific evidence behind the efficacy of the novel B3, as well as a recently published clinical trial supporting its benefit in humans. Visitors will also receive a complimentary supply of TRU NIAGEN at the booth—come early as quantities are limited.

  • What Falling Estimates & Price Mean for ChromaDex (CDXC)
    Zacks2 months ago

    What Falling Estimates & Price Mean for ChromaDex (CDXC)

    ChromaDex (CDXC) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

  • GlobeNewswire2 months ago

    ChromaDex Appoints Nobel Laureate, Professor Sir John Walker, to the Scientific Advisory Board

    ChromaDex Corp. (CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it has appointed Professor Sir John Walker, Nobel Laureate and Emeritus Director, MRC Mitochondrial Biology Unit in the University of  Cambridge, England, to the Scientific Advisory Board (SAB). ChromaDex’s co-founder and CEO, Frank Jaksch, stated, “Professor John Walker is a renowned figure in the scientific community, at the forefront of research on the synthesis of ATP in mitochondria.

  • GlobeNewswire2 months ago

    ChromaDex Corporation Reports First Quarter 2018 Financial Results

    IRVINE, Calif., May 10, 2018-- ChromaDex Corporation, a science-based, integrated nutraceutical company devoted to improving the way people age, announced today first quarter 2018 financial results.. First ...

  • ChromaDex Corporation’s (NASDAQ:CDXC) Path To Profitability
    Simply Wall St.2 months ago

    ChromaDex Corporation’s (NASDAQ:CDXC) Path To Profitability

    ChromaDex Corporation’s (NASDAQ:CDXC): ChromaDex Corporation operates as a nutraceutical company. On 31 December 2017, the US$198.07M market-cap posted a loss of -US$16.53M for its most recent financial year. Many investorsRead More...

  • GlobeNewswire3 months ago

    ChromaDex Sets First Quarter 2018 Financial Results on Thursday, May 10, 2018

    IRVINE, Calif., May 03, 2018-- ChromaDex Corp., an integrated, science-based, nutraceutical company devoted to improving the way people age, will report financial results for the first quarter of 2018 ...

  • ChromaDex (CDXC): Moving Average Crossover Alert
    Zacks3 months ago

    ChromaDex (CDXC): Moving Average Crossover Alert

    ChromaDex Corporation (CDXC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

  • GlobeNewswire3 months ago

    ChromaDex Remains Confident Amidst Inter Partes Review (IPR) Procedural Changes

    IRVINE, Calif., May 01, 2018-- ChromaDex Corp., an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that the Patent Trial and Appeal Board has published ...

  • GlobeNewswire3 months ago

    Consolidated Research: 2018 Summary Expectations for RPX, Cotiviti, NN, Dynex Capital, ChromaDex, and Cogent Communications — Fundamental Analysis, Key Performance Indications

    NEW YORK, April 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CDXC earnings conference call or presentation 8-Mar-18 9:30pm GMT

    Q4 2017 Chromadex Corp Earnings Call

  • Associated Press4 months ago

    ChromaDex reports 4Q loss

    The Irvine, California-based company said it had a loss of 17 cents per share. The natural products company posted revenue of $7.5 million in the period. For the year, the company reported that its loss ...

  • ACCESSWIRE4 months ago

    ChromaDex Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 8, 2018 / ChromaDex Corporation (NASDAQ: CDXC ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018 at 4:30 PM Eastern Time. ...